BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE (betamethasone acetate)
Betamethasone acetate and betamethasone sodium phosphate is an injectable suspension indicated for use when oral therapy is not feasible for various inflammatory, allergic, and autoimmune conditions. It is utilized across multiple specialties to manage severe or incapacitating disorders, including dermatologic, endocrine, gastrointestinal, hematologic, ophthalmic, and renal diseases. The drug also serves a therapeutic role in the palliative management of certain neoplastic diseases (leukemias and lymphomas) and the treatment of acute exacerbations of multiple sclerosis or cerebral edema.
How BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE Works
Betamethasone is a synthetic glucocorticoid that exerts potent anti-inflammatory and immunosuppressive effects. It diffuses across cell membranes and binds with high affinity to specific cytoplasmic glucocorticoid receptors. This receptor-ligand complex translocates to the nucleus, where it binds to glucocorticoid response elements (GREs) to modulate gene transcription. This results in the induction of anti-inflammatory proteins (such as lipocortins, which inhibit phospholipase A2) and the repression of pro-inflammatory cytokines, chemokines, and adhesion molecules. Additionally, it reduces capillary permeability and suppresses the humoral and cell-mediated immune responses. The combination of the sodium phosphate salt (rapidly soluble) and the acetate salt (slowly soluble) provides both immediate and sustained corticosteroid activity.
Details
- Status
- Prescription
- First Approved
- 2009-07-31
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
Companies
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE Approval History
What BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE Treats
9 indicationsBETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE is approved for 9 conditions since its original approval in 2009. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Asthma
- Atopic Dermatitis
- Contact Dermatitis
- Drug Hypersensitivity
- Allergic Rhinitis
- Serum Sickness
- Transfusion Reaction
- Exfoliative Erythroderma
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
What's emerging in BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE's indications
See all emerging drugs →Phase 3 candidates targeting molecules with no FDA-approved drug, in indications BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE treats. First-in-class if their pivotal trials read out positive.
Drugs Similar to BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE FDA Label Details
Indications & Usage
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE is indicated for the treatment of Asthma; Atopic Dermatitis; Contact Dermatitis; Drug Hypersensitivity; Allergic Rhinitis; Serum Sickness; Transfusion Reaction; Exfoliative Erythroderma; Mycosis Fungoides.
Explore on TheraRadar
Ulcerative Colitis Drug Landscape 2026
Approved therapies, pipeline drugs, and clinical trial intelligence
Related Intelligence
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.